Sight Sciences Announces Health Canada Approval of the VISCO™360 Viscosurgical System for Standalone Microinvasive Glaucoma Surgery (MIGS)

APRIL 16, 2017

Sight Sciences, Inc., a venture-backed, commercial stage ophthalmic medical device company announced today that it has received Health Canada approval for the VISCO™360 Viscosurgical System. The VISCO360 System is indicated in Canada for the microcatheterization and transluminal viscodilation of Schlemm’s canal to reduce intraocular pressure (IOP) in adult patients with open-angle glaucoma.* Performed as a standalone MIGS 
+ Read More


Sight Sciences Announces Health Canada Approval of the TRAB™360 Trabeculotomy System

DECEMBER 23, 2016

Sight Sciences, Inc., a venture-backed, commercial-stage ophthalmic medical device company announced today that it has received Health Canada approval for the TRAB™360 Trabeculotomy System. The TRAB™360 is indicated in Canada for the microcatheterization of Schlemm’s canal and cutting of trabecular meshwork to lower intraocular pressure (IOP) in patients with primary open angle glaucoma. From a 
+ Read More


Sight Sciences Announces CE Mark Approval for and Successful Commercial Experiences with the VISCO™360 Viscosurgical System for the Surgical Treatment of Glaucoma

OCTOBER 05, 2016

Sight Sciences, Inc., a venture backed, commercial stage ophthalmic medical device company announced today that the initial European commercial cases with the CE mark approved VISCO™360 Viscosurgical System will be presented Monday morning, September 12th during the European Society of Cataract and Refractive Surgeons (ESCRS) meeting in Copenhagen, Denmark. The Glaucoma II Session will be 
+ Read More